Amongst sufferers with clear cell renal cell carcinoma, improved responses have been noticed with Lenvima plus Welireg versus Keytruda plus Lenvima. © unlimit3d – inventory.adobe.com
Therapy with Lenvima (lenvatinib) together with Welireg (belzutifan) exhibited sturdy antitumor exercise and a security profile according to prior experiences of every particular person agent in sufferers with histologically confirmed domestically superior or metastatic clear cell renal cell carcinoma (ccRCC) whose illness progressed on or following PD-L1 inhibitor or VEGF-tyrosine kinase inhibitor remedy, based on cohort evaluation findings from the section 1/2 KEYMAKER-U03 substudy 03B introduced on the 2025 ASCO Genitourinary Cancers Symposium.
Glossary
Development-free survival (PFS): the period of time a affected person lives with a illness with out it worsening.
Total survival (OS): the period of time a affected person survives after being identified with or beginning remedy for a illness.
Medical profit fee (CBR): represents the proportion of sufferers who expertise a optimistic scientific profit from a remedy.
Goal response fee (ORR): the proportion of sufferers in a research who’ve a partial or full response to a remedy.
Intravenous: means “into the vein.”
Efficacy information revealed that between three arms — Keytruda (pembrolizumab)/Welireg (62 sufferers; arm B4), Lenvima/Welireg (64 sufferers; arm B5) and Keytruda/Lenvima (73 sufferers; reference arm) –– Lenvima/Welireg elicited the best variety of responses. The target response fee (ORR) in arms B4, B5, and the reference arm, respectively, have been 19.4%, 46.9% and 39.7%. In every respective arm, two, one and nil sufferers attained full responses and 10, 29 and 29 attained partial responses.
Additional information exhibited a scientific profit fee (CBR) of 32% in arm B4, 59% in arm B5 and 58% within the reference arm. Within the respective arms, the median period of response (DOR) was not reached, 22.1 months and eight.3 months.
In arm B4, arm B5, and the reference arm, the median progression-free survival (PFS) was 5.4 months, 12.5 months and 9.4 months, respectively. The six-month PFS charges within the respective arms have been 41.8%, 63.1% and 66.7%, and the 12-month charges have been 28.6%, 51.8% and 34.5%.
The median total survival (OS) was 27.4 months in arm B4, 32.3 months in arm B5 and never reached within the reference arm. The 12-month OS charges have been 67.9%, 79.5% and 81.7% within the respective arms, with 18-month charges of 57.6%, 74.4% and 73.2%.
In arm B4, 66.1% of evaluable sufferers skilled a goal lesion measurement discount, 28.8% of whom had a discount of 30% or larger. In arm B5, it was 88.3% and 60.0%, respectively, in addition to 91.8% and 49.3% within the reference arm.
“In KEYMAKER-U03 Substudy 03B, in a affected person inhabitants with many prior remedy traces, we see that Lenvima plus Welireg confirmed an ORR of [46.9%] with a median PFS of 12.5 months,” Dr. Katy Beckermann, medical oncologist and medical director of Genitourinary Medical Analysis at Tennessee Oncology, acknowledged within the presentation. “We noticed outcomes from the Keytruda plus Welireg arm have been just like these noticed within the Welireg monotherapy arm within the section 3 LITESPARK-005 research. … Outcomes from Substudy 03B confirmed promising scientific exercise within the Lenvima plus Welireg arm, and we acknowledged that the section 3 LITESPARK-011 trial was ongoing and was testing this mix in contrast [with] Cabometyx [cabozantinib].”
Within the LITESPARK-005 research, sufferers with superior ccRCC who obtained earlier immune checkpoint and antiangiogenic therapies have been randomly assigned to obtain both 120 mg of oral Welireg or 10 mg of oral Afinitor (everolimus) till illness development or unacceptable toxicity. On the first interim evaluation, the median PFS within the Welireg arm was 5.6 months, with an 18-month PFS fee of 24%. Moreover, the confirmed ORR was 21.9%, and at a second interim evaluation, the median OS was 21.4 months with an 18-month OS fee of 55.2%.
The LITESPARK-011 trial is at the moment ongoing and randomly assigning sufferers with superior RCC who skilled development after prior anti–PD-L1 remedy to obtain both Welireg/Lenvima or Cabometyx (cabozantinib). The first research finish factors are PFS and OS.
Sufferers enrolled in KEYMAKER-U03 substudy 03B have been randomly assigned to obtain Keytruda/Welireg or Lenvima/Welireg. Arms B4 (10 sufferers) and B5 (12 sufferers) had a security lead-in section whereby roughly 10 sufferers have been enrolled earlier than random task. Afterwards, sufferers have been assigned to arm B4 (52 sufferers), arm B5 (52 sufferers) or the reference arm (73 sufferers) throughout the efficacy section.
Sufferers have been stratified by Worldwide Metastatic RCC Database Consortium (IMDC) threat components and prior remedy with CTLA-4 inhibition. Moreover, sufferers have been required to have measurable illness standards by blinded unbiased evaluate committee (BICR) and a Karnofsky efficiency standing rating of 70% or larger for enrollment.
These in arm B4 have been handled with 400 mg of intravenous Keytruda each six weeks plus 120 mg of each day oral Welireg. Sufferers in arm B5 have been handled with 20 mg of each day oral lenvatinib plus 120 mg of each day oral Welireg. Sufferers within the reference arm have been handled with 400 mg of intravenous Keytruda each six weeks plus 20 mg of each day oral lenvatinib.
Throughout all cohorts, 100% of sufferers skilled any-grade facet occasions. In arms B4, B5 and the reference arm, grade 3 (extreme) to five (deadly) unwanted effects occurred in 64.5%, 77.8% and 76.7% of the respective arms. Unwanted effects resulting in dose interruption occurred in 54.8%, 71.4%, and 58.9% of every respective arm, with facet effect-related discontinuations occurring in 16.1%, 14.3% and 16.4%, and facet effect-related deaths occurring in 3.2%, 4.8% and a couple of.7% of sufferers.
Therapy-related unwanted effects occurred in 95.2%, 95.2% and 98.6% of the respective arms. Grade 3 to five treatment-related unwanted effects occurred in 41.9%, 60.3% and 49.3%, respectively, with treatment-related unwanted effects resulting in remedy continuation occurring in 11.3%, 9.5% and 12.3% of the respective arms. Therapy-related unwanted effects leading to dying occurred in 0%, 3.2% and 1.4%, respectively.
The commonest treatment-related unwanted effects within the respective arms included anemia (69.4%, 65.1%, 4.1%), diarrhea (4.8%, 42.9%, 56.2%), hypertension (0%, 36.5%, 52.1%), fatigue (24.2%, 46.0%, 34.2%) and nausea (12.9%, 38.1%, 24.7%).
Reference:“KEYMAKER-U03 Substudy 03B: pembrolizumab (pembro) and focused remedy combos for superior clear cell renal cell carcinoma (ccRCC).” By Dr Laurence Albiges. Journal of Medical Oncology.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
